CUMBERLAND PHARMACEUTICALS INC
For the period ended Mar 31, 2024. Filed May 10, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 10, 2024
CPIX$5.37+2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Equity
| Common stock · Accumulated deficit · Noncontrolling interests · Total equity | |||||
|---|---|---|---|---|---|
| Shares · Amount | |||||
| Balance, December 31, 2022 | 14,366,616 | $47,474,973 | $(11,208,841) | $(292,126) | $35,974,006 |
| Share-based compensation | 150,260 | 90,156 | — | — | 90,156 |
| Repurchase of common shares | (86,829) | (187,961) | — | — | (187,961) |
| Net income (loss) | — | — | 192,184 | (19,898) | 172,286 |
| Balance, March 31, 2023 | 14,430,047 | $47,377,168 | $(11,016,657) | $(312,024) | $36,048,487 |
| Common stock · Accumulated deficit · Noncontrolling interests · Total equity | |||||
|---|---|---|---|---|---|
| Shares · Amount | |||||
| Balance, December 31, 2023 | 14,121,833 | $47,091,602 | $(17,488,161) | $(343,572) | $29,259,869 |
| Share-based compensation | 163,991 | 78,754 | — | — | 78,754 |
| Repurchase of common shares | (125,870) | (246,599) | — | — | (246,599) |
| Net income (loss) | — | — | (1,946,263) | 43,791 | (1,902,472) |
| Balance, March 31, 2024 | 14,159,954 | $46,923,757 | $(19,434,424) | $(299,781) | $27,189,552 |
See accompanying Notes to Condensed Consolidated Financial Statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.